In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Execs On The Move: April 2023

Executive Summary

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.  

You may also be interested in...



Minute Insight: 15,000 Surgeries And More Funding For CMR Surgical

The UK-based company has just raised $165m support the ongoing commercialization of the Versius robotic platform.

Deals Shaping The Industry, August 2023

In Vivo's deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in August 2023. Data provided by Biomedtracker.

VERIGRAFT Is Taking A Fresh Approach To Personalized Tissue Grafting

The Swedish company has developed a proprietary method of personalizing venous grafts, and plans to bring it – alongside some other products – to the market.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV147713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel